Research programme: plectasin antibacterial - Sanofi

Drug Profile

Research programme: plectasin antibacterial - Sanofi

Alternative Names: NZ 2114; Plectasin derivative - Sanofi

Latest Information Update: 22 Jan 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Novozymes A/S
  • Developer Novozymes A/S; Sanofi
  • Class Peptides
  • Mechanism of Action Cell wall inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Gram-positive infections

Most Recent Events

  • 22 Jan 2014 Discontinued - Preclinical for Gram-positive infections in France (IV)
  • 17 Aug 2012 Final pharmacodynamics and pharmacokinetics data from a preclinical study in Gram-positive infections released by sanofi-aventis
  • 27 Oct 2011 Discontinued - Preclinical for Gram-positive infections in Denmark (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top